Coronary Artery Calcium (CAC) Testing in Primary Care

Part of paid clinical trials in New York, New York.

Sponsor
Weill Medical College of Cornell University
Study ID
NCT07868809
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ASCVD
  • ASCVD Management
  • Coronary Artery Calcium
  • Hyperlipidemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Our Practice Advisory (OPA) — OTHER
    This OPA, which will be within the EHR, will be visible when a patient has borderline or intermediate PREVENT-estimated 10-year ASCVD risk and lipid-lowering treatment decisions remain uncertain. The proposed actions will be: Discuss the patient's cholesterol and elevated cardiovascular risk. Guide the clinician on ordering a CAC test. Consider referral to a cardiologist or subspecialist. Consider initiation or dose titration of lipid-lowering therapy. The goal is to understand the impact of the OPA on primary care clinicians' clinical decision-making surrounding patients with borderline or intermediate ASCVD risk.

Study Details

The goal of this study is to improve how primary care providers identify and manage patients at risk for heart disease. One tool that can help with this is a coronary artery calcium (CAC) test, which looks for calcium buildup in the heart's arteries and can help estimate a person's risk of future heart problems. The main questions this study aims to answer are: Will a new electronic health record (EHR) alert that provides guidance on when to consider a CAC test be feasible and acceptable to primary care providers? Does the alert change how often providers order CAC tests, start or change the dose of cholesterol-lowering medications, and refer patients to cardiology? In this study, a new EHR alert will be implemented as part of routine clinical practice for primary care providers at Weill Cornell Internal Medicine Associates (WCIMA). The alert will provide guidance on considering a CAC test, cholesterol-lowering medication, or referral to cardiology for eligible patients. Researchers will compare clinical care before and after the alert is implemented. They will look at how often CAC tests are ordered and completed, how often cholesterol-lowering medications are started or their doses are changed, and how often patients are referred to cardiology. After the implementation period, primary care providers will also be asked to complete a brief survey and participate in an interview about the alert.

Key Dates

First listed
Oct 9, 2026
Start date
Feb 1, 2027
Status verified
Oct 2026
Primary completion
Oct 31, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: All primary care providers at Weill Cornell Internal Medicine Associates (WCIMA)
    For 8 months, an Our Practice Advisory (OPA) will be visible to primary care providers within Epic. The OPA will be activated for eligible adults without established CVD who have borderline or intermediate PREVENT-estimated 10-year ASCVD risk and for whom lipid-lowering treatment decisions remain uncertain. The proposed actions will be to order a CAC test, consider referral to cardiology, and initiate or intensify lipid-lowering therapy, including dose titration when appropriate.

Primary Outcome Measure

Feasibility of Intervention Measure [ Time Frame: Post-implementation, within 4 months following completion of the 8-month OPA implementation period ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Weill Cornell MedicineNew YorkNew York10021
Madeline R Sterling, MD, MPH, MS, FAHA
[email protected]
646-962-5029
Madeline R Sterling, MD, MPH, MS, FAHA (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site
Weill Cornell Medicine· New York, NY

Related Studies